Palatin Technologies (PTN) Net Cash Flow (2010 - 2026)
Palatin Technologies' (PTN) quarterly Net Cash Flow came in at -$4.3 million in Q1 2026, down 381.48% YoY from $1.5 million in Q1 2025, and down 132.66% on a QoQ basis from $13.2 million in Q4 2025.
Palatin Technologies (PTN) Net Cash Flow (2010 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 17 years of Net Cash Flow data on file, last reported at -$4.3 million in Q1 2026.
- Quarterly Net Cash Flow fell 381.48% year-over-year to -$4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.7 million (up 202.11% YoY) and the FY2025 annual result came in at -$7.0 million, down 552.79% from the prior year.
- Net Cash Flow fell to -$4.3 million in Q1 2026, from $13.2 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $13.2 million in Q4 2025 to a low of -$11.6 million in Q2 2023.
- A 5-year average of -$2.2 million and a median of -$1.3 million in 2025 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2023 — Net Cash Flow soared 43927.79% — and 2026, when it slumped 381.48%.
- Tracing PTN's Net Cash Flow over 5 years: stood at -$9036.0 in 2022, then soared by 43927.79% to $4.0 million in 2023, then slumped by 73.93% to $1.0 million in 2024, then surged by 1180.13% to $13.2 million in 2025, then plunged by 132.66% to -$4.3 million in 2026.
- The last three Net Cash Flow figures came in at -$4.3 million (Q1 2026), $13.2 million (Q4 2025), and -$1.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - | -4.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.32 Mn |
| Mar 31, 2026 | -4.32 Mn |
| Dec 31, 2025 | 13.22 Mn |
| Dec 31, 2025 | 13.22 Mn |
| Sep 30, 2025 | -1.29 Mn |
| Sep 30, 2025 | -1.29 Mn |
| Jun 30, 2025 | 44,203.00 |
| Jun 30, 2025 | 44,203.00 |
| Mar 31, 2025 | -896,542.00 |
| Mar 31, 2025 | -896,542.00 |
| Dec 31, 2024 | 1.03 Mn |
| Dec 31, 2024 | 1.03 Mn |
| Sep 30, 2024 | -7.14 Mn |
| Sep 30, 2024 | -7.14 Mn |
| Jun 30, 2024 | -486,692.00 |
| Jun 30, 2024 | -486,692.00 |
| Mar 31, 2024 | 528,836.00 |
| Mar 31, 2024 | 528,836.00 |
| Dec 31, 2023 | 3.96 Mn |
| Dec 31, 2023 | 3.96 Mn |